Skip to main content

Table 1 Number and phenotype of DCs administered

From: Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer

Median number of DCs administered per patient     
   no. x 106 (range)     
DC/PC3 Selected 28.15 (23.17-37.10)     
  Adherence 30.73 (25.90-31.84)     
  p-value >0.99      
DC/PC3-M1 Selected 28.86 (20.49-33.85)     
  Adherence 26.75 (24.80-34.05)     
  p-value 0.80      
Phenotype of DCs administered (median)     
   CD14+ (%) (range) CD83+ (%) (range) PI+ (%) (range)
DC/PC3 Selected 2.76 (1.85-5.71) 96.18 (86.35-98.46) 7.94 (4.36-18.06)
  Adherence 1.09 (0.82-4.41) 97.70 (90.70-98.40) 8.99 (4.81-11.50)
  p-value 0.23   >.99   0.87  
DC/PC3-M1 Selected 3.45 (1.15-7.9) 95.60 (85.67-98.49) 12.52 (4.34-17.09)
  Adherence 2.04 (1.29-6.4) 98.20 (96.80-98.90) 10.10 (5.83-12.60)
  p-value 0.87   0.12   0.72  
Median number of DC/KLH administered per patient in all three studies    
   no. x 106 (range)     
  Selected 9.04 (5.06-17.41)     
  Adherence 9.86 (4.69-16.31)     
  p-value 0.59      
Phenotype of DC/KLH administered in all three studies (median)    
   CD14+ (%) (range) CD83+ (%) (range) PI+ (%) (range)
  Selected 0.64 (0.01-2.00) 96.79 (92.35-99.30) 1.85 (0.92-9.30)
  Adherence 0.36 (0-2.82) 95.69 (86.00-99.97) 1.27 (0.34-12.19)
  p-value 0.24   0.55   0.10